# Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

> **NCT03098030** · PHASE2,PHASE3 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 483 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Dinutuximab
- **DRUG:** Irinotecan
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT03098030
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-01
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-03-26
- **Target enrollment:** 483 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03098030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03098030, "Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03098030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*